Epizyme, Inc. (NASDAQ:EPZM) – Stock analysts at Jefferies Group issued their Q3 2017 earnings per share (EPS) estimates for shares of Epizyme in a research report issued on Wednesday. Jefferies Group analyst C. Augustine forecasts that the biopharmaceutical company will post earnings of ($0.57) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $23.00 price target on the stock. Jefferies Group also issued estimates for Epizyme’s Q4 2017 earnings at ($0.59) EPS, FY2017 earnings at ($2.22) EPS, FY2018 earnings at ($2.32) EPS, FY2019 earnings at ($2.39) EPS, FY2020 earnings at ($1.95) EPS and FY2021 earnings at ($0.61) EPS.

Epizyme (NASDAQ:EPZM) last issued its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.08. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. The company had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $3.95 million. During the same period last year, the business earned ($0.49) EPS. Epizyme’s quarterly revenue was up 2027.7% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: “Epizyme, Inc. Expected to Earn Q3 2017 Earnings of ($0.57) Per Share (EPZM)” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/22/epizyme-inc-expected-to-earn-q3-2017-earnings-of-0-57-per-share-epzm.html.

Several other equities research analysts have also recently weighed in on the company. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $26.00 price target on shares of Epizyme in a research note on Tuesday. Cann reaffirmed a “buy” rating and issued a $26.00 price target on shares of Epizyme in a research note on Tuesday. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $20.00 price target on shares of Epizyme in a research note on Friday, September 15th. BidaskClub raised Epizyme from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $28.00 price target (down from $31.00) on shares of Epizyme in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $23.33.

Epizyme (EPZM) opened at 18.70 on Friday. Epizyme has a one year low of $8.38 and a one year high of $19.60. The company’s market capitalization is $1.09 billion. The company has a 50 day moving average price of $15.50 and a 200-day moving average price of $15.25.

In other news, insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction on Thursday, August 24th. The stock was sold at an average price of $15.68, for a total value of $235,200.00. Following the sale, the insider now directly owns 22,228 shares of the company’s stock, valued at $348,535.04. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director David M. Mott bought 200,000 shares of the business’s stock in a transaction dated Monday, September 18th. The stock was bought at an average cost of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the purchase, the director now owns 6,000 shares of the company’s stock, valued at approximately $91,500. The disclosure for this purchase can be found here. Over the last three months, insiders sold 48,024 shares of company stock worth $706,722. Insiders own 25.20% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc grew its stake in shares of Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after acquiring an additional 795 shares during the last quarter. UBS Asset Management Americas Inc. purchased a new stake in shares of Epizyme in the first quarter worth $175,000. BB&T Securities LLC purchased a new stake in shares of Epizyme in the second quarter worth $181,000. Trexquant Investment LP purchased a new stake in shares of Epizyme in the second quarter worth $184,000. Finally, SG Americas Securities LLC grew its stake in shares of Epizyme by 83.3% in the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock worth $202,000 after acquiring an additional 6,072 shares during the last quarter. 83.74% of the stock is currently owned by hedge funds and other institutional investors.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Earnings History and Estimates for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.